北陆药业最新公告：获得碘美普尔注射液《药品注册证书》

Core Viewpoint - Beilu Pharmaceutical (300016.SZ) has received approval from the National Medical Products Administration for the iodine-based contrast agent, Iodine Meperidine Injection, which is expected to enhance its product portfolio in the imaging diagnostics market [1] Group 1: Product Approval - The Iodine Meperidine Injection is a non-ionic monomer X-ray contrast agent used for various medical imaging diagnostics [1] - The product has been included in the National Medical Insurance Category B directory, indicating its significance in the healthcare system [1] Group 2: Market Performance - Sales of iodine-based contrast agents have been steadily increasing in the Chinese market in recent years, reflecting a growing demand for imaging diagnostics [1] - The approval of Iodine Meperidine Injection will further enrich the company's offerings in the iodine contrast agent segment [1] Group 3: Future Plans - The company plans to actively prepare for the launch of the new product following its approval [1]